Drugs / CVSQIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05252338 | Feb → Sep 2022 | influenza | CureVac | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVSQIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252338 ↗ |
| Modality | Messenger RNA (mRNA) | “Influenza mRNA Vaccine CVSQIV” NCT05252338 ↗ |
| Route | Intramuscular | “Participants will receive an intramuscular injection by needle in the deltoid area.” NCT05252338 ↗ |